Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(4):299-301; doi:10.1093/jnci/91.4.299
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gazdar, A. F.
Right arrow Articles by Minna, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gazdar, A. F.
Right arrow Articles by Minna, J. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 4, 299-301, February 17, 1999
© 1999 Oxford University Press


EDITORIALS

Molecular Detection of Early Lung Cancer

Adi F. Gazdar, John D. Minna

Affiliation of authors: Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas.

Correspondence to: Adi F. Gazdar, M.D., Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas TX 75235-8593 (e-mail: gazdar@simmons.swmed.edu).

Lung cancer is the most common cause of cancer death in the United States, and most cases follow long-term use of tobacco products (1,2). The first objective in lung cancer control is to prevent persons from starting to smoke and to help those who smoke to quit. Nevertheless, in the United States today, there are 48 million smokers, most of whom find it difficult to quit, with new smokers rapidly replacing the quitters (3) and smokers who die from their disease. In addition, about 40% of all new lung cancers are occurring in former smokers, who remain at high risk for developing lung cancer for many years after they stop smoking (4). Under current standard methods of diagnosis and treatment, less than 15% of patients with lung cancer will survive their disease (2). Most patients who achieve long-term survival are . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
R. P. Regala, R. K. Davis, A. Kunz, A. Khoor, M. Leitges, and A. P. Fields
Atypical Protein Kinase C{iota} Is Required for Bronchioalveolar Stem Cell Expansion and Lung Tumorigenesis
Cancer Res., October 1, 2009; 69(19): 7603 - 7611.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Baryshnikova, A. Destro, M. V. Infante, S. Cavuto, U. Cariboni, M. Alloisio, G. L. Ceresoli, R. Lutman, G. Brambilla, G. Chiesa, et al.
Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program
Clin. Cancer Res., March 15, 2008; 14(6): 1913 - 1919.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. P. Regala, C. Weems, L. Jamieson, A. Khoor, E. S. Edell, C. M. Lohse, and A. P. Fields
Atypical Protein Kinase C{iota} Is an Oncogene in Human Non-Small Cell Lung Cancer
Cancer Res., October 1, 2005; 65(19): 8905 - 8911.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. P. Regala, C. Weems, L. Jamieson, J. A. Copland, E. A. Thompson, and A. P. Fields
Atypical Protein Kinase C{iota} Plays a Critical Role in Human Lung Cancer Cell Growth and Tumorigenicity
J. Biol. Chem., September 2, 2005; 280(35): 31109 - 31115.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
L. L. Humphrey, S. Teutsch, and M. Johnson
Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force
Ann Intern Med, May 4, 2004; 140(9): 740 - 753.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
I. Mecklenburg, D. F. Stratakis, R. M. Huber, K. Haussinger, A. Morresi-Hauf, G. Riethmuller, and P. Kufer
Detection of Melanoma Antigen-A Expression in Sputum and Bronchial Lavage Fluid of Patients With Lung Cancer
Chest, May 1, 2004; 125(5_suppl): 164S - 166S.
[Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. R. Jett
Screening for Lung Cancer: No Longer a Taboo Subject
J. Clin. Oncol., April 15, 2002; 20(8): 1959 - 1961.
[Full Text] [PDF]


Home page
Genes Dev.Home page
G. H. Fisher, S. L. Wellen, D. Klimstra, J. M. Lenczowski, J. W. Tichelaar, M. J. Lizak, J. A. Whitsett, A. Koretsky, and H. E. Varmus
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
Genes & Dev., December 15, 2001; 15(24): 3249 - 3262.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Feng, X.-c. Xu, E. M. Youssef, and R. Lotan
Diminished Expression of S100A2, a Putative Tumor Suppressor, at Early Stage of Human Lung Carcinogenesis
Cancer Res., November 1, 2001; 61(21): 7999 - 8004.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Sueoka, N. Sueoka, Y. Goto, S. Matsuyama, H. Nishimura, M. Sato, S. Fujimura, H. Chiba, and H. Fujiki
Heterogeneous Nuclear Ribonucleoprotein B1 as Early Cancer Biomarker for Occult Cancer of Human Lungs and Bronchial Dysplasia
Cancer Res., March 1, 2001; 61(5): 1896 - 1902.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
F. R. Hirsch, W. A. Franklin, A. F. Gazdar, and P. A. Bunn Jr.
Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology
Clin. Cancer Res., January 1, 2001; 7(1): 5 - 22.
[Abstract] [Full Text]


Home page
Clin. Chem.Home page
S. J. Clayton, F. M. Scott, J. Walker, K. Callaghan, K. Haque, T. Liloglou, G. Xinarianos, S. Shawcross, P. Ceuppens, J. K. Field, et al.
K-ras Point Mutation Detection in Lung Cancer: Comparison of Two Approaches to Somatic Mutation Detection Using ARMS Allele-specific Amplification
Clin. Chem., December 1, 2000; 46(12): 1929 - 1938.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. A. Palmisano, K. K. Divine, G. Saccomanno, F. D. Gilliland, S. B. Baylin, J. G. Herman, and S. A. Belinsky
Predicting Lung Cancer by Detecting Aberrant Promoter Methylation in Sputum
Cancer Res., November 1, 2000; 60(21): 5954 - 5958.
[Abstract] [Full Text]


Home page
Am. J. Roentgenol.Home page
P. M. Boiselle, A. Ernst, and D. D. Karp
Lung Cancer Detection in the 21st Century: Potential Contributions and Challenges of Emerging Technologies
Am. J. Roentgenol., November 1, 2000; 175(5): 1215 - 1221.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Ferretti, G. Curigliano, U. Pastorino, A. Cittadini, G. Flamini, M. G. Calabrò, Tommaso De Pas, L. Orlando, M. Mandalà, M. Colleoni, et al.
Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer
Clin. Cancer Res., June 1, 2000; 6(6): 2393 - 2400.
[Abstract] [Full Text]


Home page
CarcinogenesisHome page
F. P. Perera and I.B. Weinstein
Molecular epidemiology: recent advances and future directions
Carcinogenesis, March 1, 2000; 21(3): 517 - 524.
[Abstract] [Full Text] [PDF]